TB-500
preclinicalAlso known as: Thymosin Beta-4 fragment, TB4 Ac-SDKP region
**Mechanism of Action** TB-500 (Thymosin Beta-4 fragment) is a synthetic peptide corresponding to the actin-binding domain (Ac-SDKP region) of the endogenous protein thymosin β4. It primarily functions by sequestering monomeric actin (G-actin), thereby regulating cytoskeletal dynamics and promoting cell migration. This mechanism facilitates endothelial cell motility, angiogenesis, and extracellular matrix remodeling. Additionally, TB-500 upregulates anti-inflammatory cytokines (e.g., IL-10) and downregulates pro-inflammatory mediators, contributing to tissue repair and reduced fibrosis. **Key Research Findings** Preclinical studies (16 PubMed-indexed references) demonstrate TB-500 accelerates wound healing, corneal repair, and cardiac recovery in animal models. In murine myocardial infarction models, TB-500 improved cardiac function and reduced scar size via enhanced neovascularization and myocyte survival. It also shows neuroprotective effects in spinal cord injury models by promoting axonal sprouting and reducing glial scar formation. Notably, TB-500’s short half-life (~2–4 hours) necessitates repeated dosing for sustained effects. **Clinical Relevance** Despite promising preclinical data, TB-500 remains in the preclinical stage with no completed human clinical trials. Its potential applications include chronic wound management, ischemic tissue repair, and anti-fibrotic therapy. However, safety, optimal dosing, and long-term effects in humans are uncharacterized. Regulatory approval is absent, and off-label use carries unknown risks. For research purposes only — not medical advice.
Key data
C38H68N10O14Research & studies
TB-300 improved body weight by 4.6% and FCR by 5.2%.; SB-500 significantly reduced litter Clostridia and aerobic bacteria counts.; TB-300 and SB-500 enhanced duodenal villi height and crypt-villus ratio.; All butyrate treatments increased serum total proteins and digestive enzymes.
Ac-LK was the primary metabolite with highest concentration in rats at 0-6 h intervals.; Ac-LKK was a long-term metabolite detected up to 72 hours.; No cytotoxicity was observed for TB-500 or its metabolites.; Ac-LKKTE exhibited significant wound healing activity compared to the control.
Peptide adsorption to surfaces is a concern for low-concentration measurements (ng/mL-pg/mL).; Expensive low-bind consumables are not always advantageous for recovery.; Optimal consumable choice depends on the peptide's physicochemical features.
Dilution with 200 mM phosphate buffer provides good buffering capacity without affecting peptide recoveries.; Microelution SPE showed comparable recovery, linearity, and reproducibility to cartridge SPE.; Limits of detection increased for 5 out of 17 peptides with microelution due to lower pre-concentration factor.; Microelution plates reduce solvent consumption and allow simultaneous processing of up to 96 samples.
Several metabolites were detected for each peptide after incubation with human liver microsomes, S9 fraction, and serum.; No significant differences were observed between in vitro models from different organs (liver vs. kidney).; Deamidation was not observed in any model and required evaluation with α-chymotrypsin.; In vitro models are useful tools for detecting peptidic metabolic markers in biological fluids.
Limits of detection for all seven peptides were less than 50 pg/mL.; Method validated for specificity, precision, and recovery.; Detected N-acetylated LKKTETQ and its metabolite in plasma after TB-500 administration.; First identification of in vitro metabolites for all studied peptides except TB-500 in horses.
TB-500 is a synthetic N-acetylated peptide LKKTETQ, mimicking the active site of thymosin β₄.; Method detects parent peptide and metabolites via LC/MS after solid-phase extraction.; Detection limits: 0.02 ng/mL in plasma, 0.01 ng/mL in urine.; First identification of TB-500 and its metabolites in post-administration equine samples.
Ac-LKKTETQ was detected and identified in TB-500 via HPLC/HRMS.; The peptide was synthesized using solid-phase peptide synthesis.; An analytical method for detecting Ac-LKKTETQ in plasma and urine was suggested.
Frequently asked questions
What is TB-500?
**Mechanism of Action** TB-500 (Thymosin Beta-4 fragment) is a synthetic peptide corresponding to the actin-binding domain (Ac-SDKP region) of the endogenous protein thymosin β4. It primarily functions by sequestering monomeric actin (G-actin), thereby regulating cytoskeletal dynamics and promoting cell migration. This
How does TB-500 work?
Synthetic version of the actin-binding region of thymosin β4; promotes cell migration, angiogenesis, and wound repair.
What is the research status of TB-500?
TB-500 is currently classified as preclinical, with 16 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of TB-500?
TB-500 has a molecular weight of approximately 889 g/mol (formula C38H68N10O14).
Related peptides
28-aa neuropeptide acting on VPAC1/2 receptors; vasodilatory, bronchodilatory, and anti-inflammatory.
38-aa neuropeptide of the VIP/secretin family acting on PAC1 receptors; neuroprotective and vasoregulatory.
43-aa actin-sequestering peptide that drives cell migration, angiogenesis, and repair in cardiac, corneal, and dermal tissue.
Gastric-juice-derived pentadecapeptide that promotes angiogenesis (VEGF) and tissue repair via FAK-paxillin and NO-system modulation.
C-terminal tripeptide of α-MSH with anti-inflammatory action via PepT1 uptake and NF-κB inhibition, studied in IBD models.
Copper-binding tripeptide that stimulates collagen synthesis, wound healing, and remodeling gene expression.
Build on TB-500 data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key